450 studies found for:    PAH
Show Display Options
Rank Status Study
21 Active, not recruiting DelIVery for Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Device: The Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System to deliver Remodulin Injection
22 Completed Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
23 Completed An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
24 Recruiting Carvedilol PAH A Pilot Study of Efficacy and Safety
Conditions: Pulmonary Hypertension;   Cardiac MRI <40
Intervention: Drug: Carvedilol
25 Completed A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost sodium modified release
26 Completed Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Sorafenib
27 Unknown  Pharmacogenomics in Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   Pulmonary Hypertension;   PAH WHO Group I
Interventions: Drug: Sitaxsentan;   Drug: Bosentan, Ambrisentan
28 Recruiting National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention:
29 Recruiting The Expression and Significance of MiRNA
Condition: Pulmonary Arterial Hypertension
Intervention:
30 Terminated A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001 (sodium nitrite inhalation solution)
31 Unknown  Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Conditions: Pulmonary Arterial Hypertension;   Idiopathic Pulmonary Fibrosis
Intervention: Drug: Inhaled Nitric Oxide
32 Recruiting A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
Condition: Pulmonary Arterial Hypertension (PAH)
Intervention: Drug: Macitentan
33 Completed
Has Results
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-385781A (Actelion Epoprostenol);   Drug: Flolan®
34 Recruiting Effects of Oral Sildenafil on Mortality in Adults With PAH
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: sildenafil citrate
35 Not yet recruiting The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Ambrisentan plus Spironolactone;   Drug: Ambrisentan plus Placebo
36 Unknown  Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Conditions: Pulmonary Arterial Hypertension;   Idiopathic Pulmonary Fibrosis
Interventions: Drug: bosentan;   Other: No specific intervention
37 Completed Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
Conditions: Pulmonary Arterial Hypertension;   Ayerza Syndrome;   Pulmonary Hypertension
Intervention: Drug: Iloprost or placebo
38 Recruiting Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab;   Other: Placebo
39 Recruiting SYMPHONY: A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Macitentan
40 Withdrawn Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Iloprost Inhalation Solution (Ventavis)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years